Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?

The article compares two biotech ETFs: VanEck Biotech ETF (BBH), which concentrates on 26 industry leaders like Amgen and Gilead Sciences, versus State Street SPDR S&P Biotech ETF (XBI), which provides broad exposure to 165 companies including emerging innovators. While both have identical 0.35% expense ratios and 0.4% dividend yields, XBI offers lower volatility risk and is recommended as the better buy for long-term investors seeking exposure to the industry's next big winners.

10/22/2026, 5:30 AM • The Motley Fool

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x). Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.

10/20/2026, 5:45 PM • The Motley Fool

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

Johnson & Johnson and Amgen have outperformed the broader market in 2026 despite facing near-term challenges. JNJ's medtech division struggles with its Impella heart pump facing safety concerns and recalls, but its innovative medicines segment and new products like OTTAVA robotic surgery system offer long-term growth. Amgen faces regulatory pressure on Tavneos and patent losses on denosumab, but strong pipeline candidates like MariTide and established growth drivers like Tezspire and Tepezza support its outlook. Both companies maintain excellent dividend track records, making them solid long-term income investments.

10/20/2026, 4:40 PM • The Motley Fool

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

10/19/2026, 1:00 PM • GlobeNewswire

Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH?

The article compares two healthcare ETFs: IBB (biotech-focused) and IYH (broad healthcare). IBB has delivered stronger 1-year returns (38% vs 17.4%) but exhibits higher volatility and deeper drawdowns. IYH offers lower costs, higher dividend yield, and broader diversification, making it better for most long-term investors, while IBB suits those with conviction in biotech momentum who can tolerate volatility.

10/11/2026, 7:09 PM • The Motley Fool

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

10/10/2026, 10:15 PM • The Motley Fool

A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens

Some economists predict a market downturn and recession by end of 2027. The article recommends two pharmaceutical stocks—AbbVie and Amgen—as defensive investments that have historically weathered downturns well due to their diversified drug portfolios, consistent revenue from chronic disease treatments, strong pipelines, and reliable dividend payments.

10/09/2026, 10:30 AM • The Motley Fool

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

10/01/2026, 12:30 PM • The Motley Fool

Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight

The coronary artery disease treatment landscape is rapidly evolving with 20+ pharmaceutical companies actively developing 22+ pipeline drugs. Key players including Roche, Verve Therapeutics, Amgen, and others are advancing therapies targeting residual cardiovascular risk through novel mechanisms such as Factor XI inhibitors, gene therapy, and anti-inflammatory approaches. Recent clinical trial progress includes positive Phase IIa results for vortosiran and Phase II initiation of SRSD107, signaling growing momentum in addressing high-risk CAD patients beyond conventional treatments.

09/30/2026, 1:00 PM • GlobeNewswire

Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities

The HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.

09/30/2026, 4:59 AM • GlobeNewswire

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

09/30/2026, 4:58 AM • GlobeNewswire

Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight

The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.

09/24/2026, 1:00 PM • GlobeNewswire

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

09/22/2026, 10:04 PM • The Motley Fool

The Schwab U.S. Dividend Equity ETF Is Near Its All-Time High: Is It Still a Good Buy?

The Schwab U.S. Dividend Equity ETF (SCHD) has surged 22% this year and hit an all-time high, prompting questions about valuation. Despite the gains, the ETF maintains a reasonable price-to-earnings multiple of less than 20 (below the S&P 500's 23) and offers a 3% dividend yield, making it still attractive for income-focused investors seeking safety and quality dividend stocks.

09/22/2026, 12:10 PM • The Motley Fool

Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities

A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.

09/22/2026, 10:59 AM • GlobeNewswire